| Date Filed | Type | Description |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/20/2023 |
8-K
| Quarterly results |
| 05/19/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/11/2023 |
8-K
| Quarterly results|
Docs:
|
"Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights Presented initial preclinical data from ETX-123, Eliem's lead Kv7 program candidate, demonstrating a promising profile and confirming the proposed mechanism of action on neuronal excitability Additional preclinical data updates for ETX-123 expected in 2023 SEATTLE and CAMBRIDGE, UK, -- – May 11, 2023 – Eliem Therapeutics, Inc. , a biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today provided a business update and reported financial results for the quarter ended March 31, 2023. “We were excited to share our initial preclinical ...",
"Clinical Stage Neurology Company Focused on Neuronal Excitability Disorders Corporate Presentation" |
|
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/06/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/06/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/06/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/21/2023 |
3
| Pimblett Emily (Chief Accounting Officer) has filed a Form 3 on Eliem Therapeutics, Inc. |
| 03/16/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/14/2023 |
4
| Morisset Valerie (EVP, R&D and CSO) has filed a Form 4 on Eliem Therapeutics, Inc.|
Txns:
| Exercised 255,219 options to buy
@ $0.002, valued at
$510.4
Exercised 61,191 options to buy
@ $0.0002, valued at
$12.2 |
|
| 03/08/2023 |
SC 13G/A
| Intermediate Capital Group plc reports a 7.5% stake in Eliem Therapeutics, Inc. |
| 03/06/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/06/2023 |
8-K
| Quarterly results|
Docs:
|
"Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights Progressing IND-enabling studies for ETX-123 and further preclinical development of Kv7.2/3 channel opener program Implemented corporate reorganization and pipeline reprioritization extending cash runway into 2027 SEATTLE and CAMBRIDGE, UK, -- – March 6, 2023 – Eliem Therapeutics, Inc. , a biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today provided a business update and reported financial results for the quarter and year ended December 31, 2022. “We are excited to advance our Kv7 program forward with ETX-123 as..." |
|
| 03/06/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/14/2023 |
SC 13G/A
| SAMLYN CAPITAL, LLC reports a 0% stake in Eliem Therapeutics, Inc. |
| 02/08/2023 |
SC 13G/A
| BML Investment Partners, L.P. reports a 7.1% stake in Eliem Therapeutics, Inc. |
| 01/24/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 12/20/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
8-K
| Quarterly results|
Docs:
|
"Eliem Therapeutics Reports Third Quarter Financial and Business Highlights Positioned to initiate ETX-155 Phase 2a trial in major depressive disorder in the first quarter of 2023 with 60-milligram dose Progressing IND-enabling studies for two Kv7 pre-candidates with safety studies planned in the first quarter of 2023 Cash runway expected to fund operations into 2025 SEATTLE and CAMBRIDGE, UK, -- – November 14, 2022 – Eliem Therapeutics, Inc. , a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today provided a business update and reported financial results for the quarter ended September 30, 2022. ...",
"2 NO FOOD EFFECT3 ETX-155" |
|
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/02/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/02/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/02/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/02/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/05/2022 |
8-K
| Quarterly results |
| 09/22/2022 |
SC 13G
| ICG Life Sciences SCSp reports a 7.5% stake in Eliem Therapeutics, Inc. |
| 08/15/2022 |
8-K
| Quarterly results |
| 08/15/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 07/18/2022 |
8-K
| Quarterly results |
| 06/01/2022 |
4
| Tate Simon (Director) has filed a Form 4 on Eliem Therapeutics, Inc.|
Txns:
| Granted 10,000 options to buy
@ $3.46, valued at
$34.6k
|
|
| 06/01/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/01/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/01/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|